A 34-year-old woman developed symptomatic arachnoiditis ossificans and an arachnoid cyst as a consequence of tuberculous meningitis adequately treated 20 years before. Surgical decompression of the cyst stopped the progression of her spastic paraparesis. Pathologic examination confirmed the presence of ossification of the arachnoid.
COMMUNICATIONS 797 7. Klieser E, Lehmann E, Tegeler J. Double-blind comparison of 3 x 75 mg zotepine and 3 x 4 mg haloperidol in acute schizophrenics. Fortschr Neurol Psychiatr 1991 39: 14-17, 8. Barnas C, Stuppack CH, Miller C, Haring C, Sperner-Untenveger B, Fleischhacker WW. Zotepine: Treatment of chronic schizophrenic patients presenting with predominantly negative symptoms-a double-blind study versus haloperidol. Fortschr Neurol Psychiatry 1991;59:3640. 9. Altar CA, Boyar WC, Wasley A, Liebman JM, Wood PL, Gerhardt SG. Dopamine neurochernical profile of atypical antipsychotics resembles that of D,-antagonists. Naunyn-Schmiedeberg's Arch Pharmacol 1988;338: 162-168. 10. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 1992;260576--580. 11. Van To1 HHM, Bunzow JR, Guan H-C, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991 ;350:610-614. 12. Uchida S, Honda F, Otsuka M, et al. Pharmacological study of [2-chloro-1 I-(2-dimethyl-aminomethoxy) dibenzo[b,flthiepine] (zotepine), a new neuroleptic drug. Drug Res 1979; 29:158&1594.
A total of 26 patients were treated with pergolide mesylate, a semi-synthetic ergot derivative with the property of direct dopamine activity. Of these patients, 18 suffered from late failure of L-dopa, while the remaining 8 had never before been treated with L-dopa. The aim of the trial was to study the activity of pergolide, either by giving it to untreated patients or by reducing as much as possible the L-dopa given in patients with parkinsonism. Adverse effects and failure rate were reduced by slowly increasing the daily dosage, by giving considerable dose flexibility whenever side-effects were manifest, and by the use of relatively low doses (mean of 3.8 mg in the L-dopa-group and 2.9 in the other group). At present, from 26 patients, 13 (50%) still remain in the study for an average treatment period of 16 months (3 weeks to 25 months for the group as a whole). All patients experienced a beneficial effect from pergolide, especially during the first months of treatment, in selfcare, rigidity, gait and automatic movements. Slight or no improvement was seen in tremor, speech and posture. The most frequent side-effects were nausea and vomiting (in the initial phase of the treatment), insomnia and psychotoxic reactions (mostly periods of confusion accompanied by visual hallucinations and paranoid illusions). The study indicated that pergolide mesylate is a useful additive for treatment of parkinsonism, but special attention should be paid to the important psychotoxic adverse effects that may appear, even at a low dose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.